Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Adenocarcinoma × cabazitaxel × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 7 Recurrence 2 Prostate Cancer, Hereditary, 7 1 Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Carcinoma 1 Adenocarcinoma 1

Interventions

pembrolizumab 6 Oxaliplatin 6 Paclitaxel 3 Leucovorin 3 Fluorouracil 3 Docetaxel 3 zolbetuximab 2 durvalumab 2 camrelizumab 2 apatinib 2 S 1 (combination) 2 Carboplatin 2 Capecitabine 2 vistusertib 1 trifluridine tipiracil drug combination 1 trastuzumab deruxtecan 1 tislelizumab 1 tepotinib 1 sitravatinib 1 relugolix 1 regorafenib 1 palbociclib 1 osimertinib 1 lenvatinib 1 dabrafenib 1 ceralasertib 1 capivasertib 1 cabazitaxel 1 X-Rays 1 Vinorelbine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01952223 2025-07-30

PEACE2

UNICANCER

Phase 3 Active not recruiting

Adenocarcinoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡